New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw

Oral Diseases

Volumn 18, Issue 6, 2012, Pages 580-585

  Balla, B ^a   Vaszilko, M ^a   Kosa J P ^a   Podani, J ^b   Takacs I ^a   Tobias B ^a   Nagy, Z ^a   Lazáry, Á ^c   Lakatos, P ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c National Center for Spinal Disorders   (Hungary)

Author keywords

CYP2C8 polymorphism; Mandible; Maxilla; Osteonecrosis of the jaws; Principal component analysis

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CYTOCHROME P450 2C8; GENOMIC DNA; IBANDRONIC ACID; LIPID; PAMIDRONIC ACID; PARATHYROID HORMONE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; BONE METASTASIS; BREAST CANCER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; GENETIC ANALYSIS; HORMONAL THERAPY; HUMAN; HUNGARY; JAW OSTEONECROSIS; LIPID BLOOD LEVEL; MALE; MANDIBLE; MULTIPLE MYELOMA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENINE; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ARYL HYDROCARBON HYDROXYLASES; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CALCIUM; DIPHOSPHONATES; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENOTYPE; GUANINE; HUMANS; HUNGARY; LIPIDS; MALE; MANDIBULAR DISEASES; MAXILLARY DISEASES; MIDDLE AGED; PARATHYROID HORMONE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRINCIPAL COMPONENT ANALYSIS; RECURRENCE; TIME FACTORS; VITAMIN D;

EID: 84864861154     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2012.01912.x     Document Type: Article

References (24)

1. Capdevila JH, Falck JR, Harris RC (2000). Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41: 163-181.
2. Czerwinski E, Badurski JE, Marcinowska-Suchowierska E et al (2007). Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil 9: 337-356.
3. English BC, Baum CE, Adelberg DE et al (2010). A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag 6: 579-583.
4. Filleul O, Crompot E, Saussez S (2010). Bisphosphonate-induced osteonecrosis of the jaw: a review of 2, 400 patient cases. J Cancer Res Clin Oncol 136: 1117-1124.
5. Hoff AO, Toth BB, Altundag K et al (2008). Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23: 826-836.
6. Jeong S, Woo MM, Flockhart DA et al (2009). Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4, 4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol 64: 867-875.
7. Jolliffe I (1986). Principal component analysis. Springer: New York.
8. Kamdem LK, Liu Y, Stearns V et al (2010). In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol 70: 854-869.
9. Lippi G, Braga V, Adami S et al (1998). Modification of serum apolipoprotein A-I, apolipoprotein B and lipoprotein(a) levels after bisphosphonates-induced acute phase response. Clin Chim Acta 271: 79-87.
10. Marx RE, Sawatari Y, Fortin M et al (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63: 1567-1575.
11. Montagnani A, Gonnelli S, Cepollaro C et al (2003). Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate. Bone 32: 15-19.
12. Otto S, Pautke C, Opelz C et al (2010). Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 68: 2837-2845.
13. Podani J (2000). Introduction to the exploration of multivariate biological data. Backhuys: Leiden.
14. Podani J (2001). SYN-TAX 2000. User's manual. Scientia: Budapest.
15. Reid IR, Bolland MJ, Grey AB (2007). Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41: 318-320.
16. Rizzoli R, Burlet N, Cahall D et al (2008). Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42: 841-847.
17. Sarasquete ME, Garcia-Sanz R, Marin L et al (2008). Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112: 2709-2712.
18. Sarasquete ME, Gonzalez M, San Miguel JF et al (2009). Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 15: 382-387.
19. Singer FR, Clemens TL, Eusebio RA et al (1998). Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J Clin Endocrinol Metab 83: 1906-1910.
20. Such E, Cervera J, Terpos E et al (2011). CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica 96: 1557-1559.
21. Viccica G, Vignali E, Marcocci C (2007). Role of the cholesterol biosynthetic pathway in osteoblastic differentiation. J Endocrinol Invest 30: 8-12.
22. Walsky RL, Gaman EA, Obach RS (2005). Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45: 68-78.
23. Walter C, Klein MO, Pabst A et al (2010). Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14: 35-41.
24. Woo SB, Hellstein JW, Kalmar JR (2006). Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753-761.